CHD5是一种人体1p36的瘤抑制剂
Anindya Bagchi1, Cristian Papazoglu, Ying Wu
1Cold Spring Harbor Laboratory, Cold Spring Harbor, NY 11724, USA.
Cell
|February 10, 2007
概括
科学家们确定了染色体螺旋酶DNA结合域5 (Chd5) 作为一种瘤抑制基因. 该基因在1p36区域的删除与各种人类癌症有关,提供了新的治疗点.
科学领域:
- 遗传学 是一个遗传学.
- 在瘤学瘤学.
- 分子生物学分子生物学
背景情况:
- 癌症基因发现通常涉及分析染色体的收益和损失.
- 1p36染色体区域的删除在各种人类癌症中很常见,这表明存在关键瘤抑制基因.
- 到目前为止,1p36的特定瘤抑制基因仍然未被确定.
研究的目的:
- 功能性地识别位于1p36染色体区域的瘤抑制基因.
- 调查已识别的基因在瘤发生中的作用及其作用机制.
主要方法:
- 利用染色体工程来创建具有1p36区域的特定收益和损失的小鼠模型.
- 进行了功能性测试,以评估Chd5对细胞增殖,细胞亡和衰老等细胞过程的影响.
- 分析了p19 ((Arf) /p53通路在Chd5的瘤抑制活性中的参与.
主要成果:
- 功能性识别的染色体基酶DNA结合域5 (Chd5) 作为瘤抑制剂.
- 证明Chd5通过p19 (Arf) /p53通路调节细胞增殖,细胞亡和衰老.
- 提供证据表明CHD5删除在人类癌症中.
结论:
- Chd5通过p19(Arf) /p53通路控制关键细胞过程,作为关键瘤抑制剂.
- 切除CHD5与人类瘤发生有关.
- 对Chd5的鉴定为开发向癌症治疗开辟了新的可能性.
相关概念视频
Inhibition of Cdk Activity
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Abnormal Proliferation
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Inhibition of CDK Activity
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...


